RCT: Tremelimumab plus Durvalumab in unresectable hepatocellular carcinoma.
9 Jun, 2022 | 10:24h | UTCTremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma – NEJM Evidence
Commentary on Twitter
Durvalumab plus a single dose of tremelimumab increased overall survival by just over 2.5 months in patients with unresectable hepatocellular carcinoma who had not received previous systemic therapy. Read more about the HIMALAYA trial by @GABOUALFA et al.: https://t.co/8d2qp54OLt pic.twitter.com/AA1RlSEP2a
— NEJM Evidence (@NEJMEvidence) June 6, 2022